Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President & CFO | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 449,434 |
Ending reported balance
After 2026-03-04 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-03-03 · Exercise / conversion · Acquired 45,290 · Balance 167,442 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2026-03-03 · Tax withholding · Disposed 16,182 · Balance 151,260 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Row 3 · 2026-03-03 · Exercise / conversion · Acquired 57,339 · Balance 208,599 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 4 · 2026-03-03 · Tax withholding · Disposed 24,251 · Balance 184,348 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Row 5 · 2026-03-03 · Exercise / conversion · Acquired 28,538 · Balance 212,886 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 6 · 2026-03-03 · Tax withholding · Disposed 14,298 · Balance 198,588 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Row 7 · 2026-03-03 · Exercise / conversion · Acquired 458,716 · Balance 657,304 F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Row 8 · 2026-03-03 · Tax withholding · Disposed 229,817 · Balance 427,487 F5: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Row 9 · 2026-03-04 · Exercise / conversion · Acquired 43,982 · Balance 471,469 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 10 · 2026-03-04 · Tax withholding · Disposed 22,035 · Balance 449,434 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-03 · Exercise / conversion · Disposed 45,290 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,340 |
Reported balance
After 2026-03-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-03 · Exercise / conversion · Disposed 57,339 · Balance 57,340 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 85,617 |
Reported balance
After 2026-03-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-03 · Exercise / conversion · Disposed 28,538 · Balance 85,617 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8: On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 87,963 |
Reported balance
After 2026-03-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-04 · Exercise / conversion · Disposed 49,982 · Balance 87,963 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9: On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-03 · Exercise / conversion · Disposed 458,716 · Balance 0 F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
F5: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
F6: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F7: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F8: On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F9: On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2027-06-29 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2028-07-27 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-05-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2030-05-13 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 102,040 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 116,370 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 13,257 | $5.47 | $72,515.79 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · nonDerivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 403,780 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 87,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018472 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,720 Underlying: Class A Common Stock · 87,719 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 87,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018472 · doc4.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 458,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016933 · doc4.xml · derivative · entry 4 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,716 Underlying: Class A Common Stock · 458,716 shares Expires not disclosed F5 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · shares: Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F6 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F6 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F6 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F6 · balance_after: Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 229,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016933 · doc4.xml · derivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,358 Underlying: Class A Common Stock · 229,358 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2024. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016933 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,870 Underlying: Class A Common Stock · 45,289 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016933 · doc4.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015516 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,394 Underlying: Class A Common Stock · 36,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-015516 · doc4.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 87,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-018891 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,439 Underlying: Class A Common Stock · 87,719 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 87,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-018891 · doc4.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 362,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016050 · doc4.xml · derivative · entry 4 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,318 Underlying: Class A Common Stock · 362,318 shares Expires not disclosed F5 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · shares: Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F6 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F6 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F6 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 181,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016050 · doc4.xml · derivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,159 Underlying: Class A Common Stock · 181,159 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016050 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,591 Underlying: Class A Common Stock · 36,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016050 · doc4.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 116,370 | $5.92 Strike: $3.58 | $688,910.40 |
DisclosureSEC source: 0001104659-21-136399 · tm2131118-3_4seq1.xml · derivative · entry 5 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 116,370 shares Expires 2031-05-12 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 102,040 | $5.06 Strike: $4.44 | $516,322.40 |
DisclosureSEC source: 0001104659-21-136399 · tm2131118-3_4seq1.xml · derivative · entry 4 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 102,040 shares Expires 2030-05-13 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $7.21 Strike: $2.29 | $721,000.00 |
DisclosureSEC source: 0001104659-21-136399 · tm2131118-3_4seq1.xml · derivative · entry 3 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $6.15 Strike: $3.35 | $307,500.00 |
DisclosureSEC source: 0001104659-21-136399 · tm2131118-3_4seq1.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2028-07-27 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $5.38 Strike: $4.12 | $269,000.00 |
DisclosureSEC source: 0001104659-21-136399 · tm2131118-3_4seq1.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2027-06-29 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:04 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 116,370 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001593968-21-001309 · primary_01.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,370 Underlying: Common stock · 116,370 shares Expires 2031-05-12 F1 · derivative.exercise_date: The stock option vests in full on the first anniversary of the grant date, or May 12, 2022 Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 87,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020434 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,158 Underlying: Class A Common Stock · 87,719 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 12,2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 12,2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 87,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-020434 · doc4.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 289,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016983 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,576 Underlying: Class A Common Stock · 289,576 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F5 · derivative.exercise_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. F5 · derivative.expiration_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 144,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016983 · doc4.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,788 Underlying: Class A Common Stock · 144,788 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022. Read SEC document |
| May 13, 2020 Filed May 14, 2020 16:28 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 102,040 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001593968-20-001176 · primary_01.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,040 Underlying: Common stock, $0.001 par value · 102,040 shares Expires 2030-05-13 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 13, 2021. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:02 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 701,754 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008429 · doc4.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,754 Underlying: Class A Common Stock · 701,754 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F5 · derivative.exercise_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. F5 · derivative.expiration_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:02 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 350,877 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008429 · doc4.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,877 Underlying: Class A Common Stock · 350,877 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 12, 2021. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 12, 2021. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:52 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 100,000 | $2.29 Strike: $2.29 | $229,000.00 |
DisclosureSEC source: 0001593968-19-001125 · primary_01.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 15, 2020. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 17:10 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 50,000 | $3.35 Strike: $3.35 | $167,500.00 |
DisclosureSEC source: 0001593968-18-001079 · primary_01.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2028-07-27 F1 · derivative.exercise_date: The option becomes vested and exercisable on July 27, 2018. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 18:49 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 50,000 | $4.12 Strike: $4.12 | $206,000.00 |
DisclosureSEC source: 0001593968-17-000845 · primary_01.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: The option becomes vested and exercisable on June 29, 2018. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.